Format
Sort by
Items per page

Send to

Choose Destination

Best matches for STÖRKEL S[au]:

Retraction. Schwerdtle RF et al. Cancer Res. (1999)

Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Jin F et al. Cancer Prev Res (Phila). (2017)

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. Chamie K et al. JAMA Oncol. (2017)

Search results

Items: 1 to 50 of 219

1.

Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915].

Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N.

Eur Urol Focus. 2019 Sep;5(5):920. doi: 10.1016/j.euf.2019.08.010. Epub 2019 Aug 30. No abstract available.

PMID:
31474581
2.

[Günther Schubert : August 17, 1930-October 23, 2017].

Störkel S.

Pathologe. 2018 Dec;39(Suppl 2):353-354. doi: 10.1007/s00292-018-0490-2. German. No abstract available.

PMID:
30203218
3.

Diode-pumped neodymium:yttrium aluminum garnet laser effects on the visceral pleura in an ex vivo porcine lung model†.

Bölükbas S, Greve T, Biancosino C, Eberlein M, Schumacher S, Gödde D, Störkel S, Redwan B.

Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):339-343. doi: 10.1093/icvts/ivy254.

PMID:
30189016
4.

MicroRNAs as Urinary Biomarker for Oncocytoma.

von Brandenstein M, Schlosser M, Herden J, Heidenreich A, Störkel S, Fries JWU.

Dis Markers. 2018 Jul 16;2018:6979073. doi: 10.1155/2018/6979073. eCollection 2018.

5.

Extra nodular metastasis is a poor prognostic factor for overall survival in node-positive patients with colorectal cancer.

Ambe PC, Gödde D, Störkel S, Zirngibl H, Bönicke L.

Int J Colorectal Dis. 2018 Apr;33(4):403-409. doi: 10.1007/s00384-018-2991-0. Epub 2018 Mar 8.

PMID:
29520454
6.

Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.

Jin F, Thaiparambil J, Donepudi SR, Vantaku V, Piyarathna DWB, Maity S, Krishnapuram R, Putluri V, Gu F, Purwaha P, Bhowmik SK, Ambati CR, von Rundstedt FC, Roghmann F, Berg S, Noldus J, Rajapakshe K, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Kaipparettu BA, Karanam B, Terris MK, Kavuri SM, Lerner SP, Kheradmand F, Coarfa C, Sreekumar A, Lotan Y, El-Zein R, Putluri N.

Cancer Prev Res (Phila). 2017 Oct;10(10):588-597. doi: 10.1158/1940-6207.CAPR-17-0198. Epub 2017 Aug 29.

7.

Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder.

Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N.

Eur Urol Focus. 2018 Dec;4(6):907-915. doi: 10.1016/j.euf.2017.04.005. Epub 2017 Apr 20. Erratum in: Eur Urol Focus. 2019 Sep;5(5):920.

8.

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016.

van den Bruck R, Weil PP, Ziegenhals T, Schreiner P, Juranek S, Gödde D, Vogel S, Schuster F, Orth V, Dörner J, Pembaur D, Röper M, Störkel S, Zirngibl H, Wirth S, Jenke ACW, Postberg J, Boy N, Heringer J, Haege G, Glahn EM, Hoffmann GF, Garbade SF, Burgard P, Kölker S, Chao CM, Yahya F, Moiseenko A, Shrestha A, Ahmadvand N, Quantius J, Wilhelm J, El-Agha E, Zimmer KP, Bellusci S, Staufner C, Kölker S, Prokisch H, Hoffmann GF, Seeliger S, Müller M, Hippe A, Steinkraus H, Wauer R, Lachmann B, Hofmann SR, Hedrich CM, Zierk J, Arzideh F, Haeckel R, Rascher W, Rauh M, Metzler M, Thieme S, Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Hedrich CM, Bonifacio E, Berner R, Brenner S, Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H, Bohne F, Langer D, Cencic R, Eggermann T, Zechner U, Pelletier J, Zepp F, Enklaar T, Prawitt D, Pech M, Weckmann M, Heinsen FA, Franke A, Happle C, Dittrich AM, Hansen G, Fuchs O, von Mutius E, Oliver BG, Kopp MV, Paret C, Russo A, Theruvath J, Keller B, El Malki K, Lehmann N, Wingerter A, Neu MA, Aslihan GA, Wagner W, Sommer C, Pietsch T, Seidmann L, Faber J, Schreiner F, Ackermann M, Michalik M, Rother E, Bilkei-Gorzo A, Racz I, Bindila L, Lutz B, Dötsch J, Zimmer A, Woelfle J, Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G, Stein R, Hofmann SR, Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ, Loges NT, Frommer AT, Wallmeier J, Omran H, Öner-Sieben S, Gimpfl M, Rozman J, Irmler M, Beckers J, De Angelis MH, Roscher A, Wolf E, Ensenauer R, Nemes K, Frühwald M, Hasselblatt M, Siebert R, Kordes U, Kool M, Wang H, Hardy H, Refai O, Barwick KES, Zimmerman HH, Weis J, Baple EL, Crosby AH, Cirak S, Hellmuth C, Uhl O, Standl M, Heinrich J, Thiering E, Koletzko B, Blümel L, Kerl K, Picard D, Frühwald MC, Liebau MC, Reifenberger G, Borkhardt A, Hasselblatt M, Remke M, Tews D, Wabitsch M, Fischer-Posovszky P, Westhoff MA, Nonnenmacher L, Langhans J, Schneele L, Trenkler N, Debatin KM.

Mol Cell Pediatr. 2017 May;4(Suppl 1):5. doi: 10.1186/s40348-017-0071-0. No abstract available.

9.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

10.

Calprotectin could be a potential biomarker for acute appendicitis.

Ambe PC, Gödde D, Bönicke L, Papadakis M, Störkel S, Zirngibl H.

J Transl Med. 2016 Apr 27;14(1):107. doi: 10.1186/s12967-016-0863-3.

11.

Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.

von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB, Lotan Y, Gödde D, Roth S, Störkel S, Levitt JM, Michailidis G, Sreekumar A, Lerner SP, Coarfa C, Putluri N.

J Urol. 2016 Jun;195(6):1911-9. doi: 10.1016/j.juro.2016.01.039. Epub 2016 Jan 21.

12.

Aquaporin-1 and 8 expression in the gallbladder mucosa might not be associated with the development of gallbladder stones in humans.

Ambe PC, Gödde D, Zirngibl H, Störkel S.

Eur J Clin Invest. 2016 Mar;46(3):227-33. doi: 10.1111/eci.12586. Epub 2016 Jan 21.

PMID:
26707370
13.

Vimentin 3, the new hope, differentiating RCC versus oncocytoma.

von Brandenstein M, Puetz K, Schlosser M, Löser H, Kallinowski JP, Gödde D, Buettner R, Störkel S, Fries JW.

Dis Markers. 2015;2015:368534. doi: 10.1155/2015/368534. Epub 2015 Apr 7.

14.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
15.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.

PMID:
25445556
16.

Immunohistochemical analysis of cytochrome C oxidase facilitates differentiation between oncocytoma and chromophobe renal cell carcinoma.

Adam AC, Scriba A, Ortmann M, Huss S, Kahl P, Steiner S, Störkel S, Büttner R.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):54-9. doi: 10.1097/PAI.0000000000000036.

PMID:
25265428
17.

Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer.

Amendt C, Staub E, Friese-Hamim M, Störkel S, Stroh C.

Clin Cancer Res. 2014 Sep 1;20(17):4478-87. doi: 10.1158/1078-0432.CCR-13-3385. Epub 2014 Jun 19.

18.

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.

Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE.

Oncol Res Treat. 2014;37(3):136-41. doi: 10.1159/000360179. Epub 2014 Feb 21.

19.

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K.

Eur Urol. 2014 Aug;66(2):243-50. doi: 10.1016/j.eururo.2014.03.011. Epub 2014 Mar 21.

PMID:
24680359
20.

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA.

J Thorac Oncol. 2014 May;9(5):717-24. doi: 10.1097/JTO.0000000000000141.

21.

[T1 bladder cancer: role of documentation for bladder tumor findings and targeted second resection].

Lazica DA, Böttcher S, Degener S, von Rundstedt FC, Brandt AS, Störkel S, Roth S.

Urologe A. 2013 Aug;52(8):1110-7. doi: 10.1007/s00120-013-3206-5. German.

PMID:
23754611
22.

[Impact of operator experience on TURB of high-grade non-muscle-invasive bladder cancer--analysis of 254 second resections at a university teaching hospital].

Lazica DA, Degener S, Böttcher S, Brandt AS, Störkel S, Roth S.

Aktuelle Urol. 2013 May;44(3):196-200. doi: 10.1055/s-0033-1345144. Epub 2013 May 27. German.

PMID:
23712276
23.

[T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].

Lazica DA, Böttcher S, Degener S, von Rundstedt FC, Brandt AS, Roth S, Störkel S, Mathers MJ.

Aktuelle Urol. 2013 Mar;44(2):124-8. doi: 10.1055/s-0033-1334962. Epub 2013 Apr 11. German.

PMID:
23580383
24.

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.

Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T.

Eur Urol. 2013 Aug;64(2):193-8. doi: 10.1016/j.eururo.2013.03.029. Epub 2013 Mar 17.

PMID:
23522911
25.

Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

Rüschoff J, Kerr KM, Grote HJ, Middel P, von Heydebreck A, Alves VA, Baldus SE, Büttner R, Carvalho L, Fink L, Jochum W, Lo AW, López-Ríos F, Marx A, Molina TJ, Olszewski WT, Rieker RJ, Volante M, Thunnissen E, Wrba F, Celik I, Störkel S.

Arch Pathol Lab Med. 2013 Sep;137(9):1255-61. doi: 10.5858/arpa.2012-0605-OA. Epub 2012 Dec 27.

PMID:
23270410
26.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F.

Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19.

PMID:
23265711
27.

Two papillary renal cell carcinomas of different origin following renal transplantation (Case report).

Gerth HU, Pohlen M, Thoennissen NH, Suwelack B, Pavenstädt HJ, Störkel S, Abbas M, Spieker T, Thölking G.

Oncol Lett. 2012 Jul;4(1):80-82. Epub 2012 May 4.

28.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ.

Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4.

PMID:
22056021
29.

Retroperitoneal tumours: the pathologist's view.

Störkel S.

Khirurgiia (Sofiia). 2011;(3):15-8.

PMID:
23844457
30.

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.

Ann Oncol. 2011 May;22(5):1078-87. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3.

31.

Pharyngeal selective brain cooling is associated with reduced CNS cortical lesion after experimental traumatic brain injury in rats.

Doll H, Maegele M, Bohl J, Störkel S, Kipfmueller F, Schaefer U, Angelov D, Wirth S, Truebel H.

J Neurotrauma. 2010 Dec;27(12):2245-54. doi: 10.1089/neu.2010.1505.

PMID:
20939694
32.

[Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].

Störkel S.

Pathologe. 2010 Feb;31(1):50-3. doi: 10.1007/s00292-009-1243-z. Review. German.

PMID:
20084384
33.

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.

J Clin Oncol. 2009 Jun 20;27(18):2924-30. doi: 10.1200/JCO.2008.18.9563. Epub 2009 May 11.

PMID:
19433689
34.

Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications.

May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S.

Eur Urol. 2010 May;57(5):850-8. doi: 10.1016/j.eururo.2009.03.052. Epub 2009 Mar 31.

PMID:
19346063
35.

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.

Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong KK, Bokemeyer C, Heinrich MC.

Mol Cancer Ther. 2009 Mar;8(3):481-9. doi: 10.1158/1535-7163.MCT-08-1068. Epub 2009 Mar 10.

36.

Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.

Gunia S, May M, Scholmann K, Störkel S, Hoschke B, Koch S, Dietel M, Kristiansen G.

Virchows Arch. 2008 Aug;453(2):165-70. doi: 10.1007/s00428-008-0638-1. Epub 2008 Jul 22.

PMID:
18648853
37.

[Pathology in Wuppertal].

Störkel S.

Verh Dtsch Ges Pathol. 2005;89:10-4. German. No abstract available.

PMID:
18035668
38.

["Retroperitoneal Fibrosis" (RPF) Urologic Cooperation and Research Project].

Brandt AS, Soares SB, Fehr A, Kukuk S, Mathers MJ, Störkel S, Lerch H, Bockisch A, Haage P, Vollmann R, Thürmann P, Roth S.

Urologe A. 2007 Sep;46(9):1302-4. German. No abstract available.

PMID:
17668163
39.

[Villous adenoma of the renal pelvis and ureter].

Frickmann H, Jungblut S, Bargon J, Willenbrock K, Störkel S, Hanke P.

Urologe A. 2006 Nov;45(11):1435-7. German.

PMID:
16900367
40.

Human macrophages simultaneously express membrane-C1q and Fc-receptors for IgG.

Terheyden P, Loos M, Störkel S, Kaul M.

Immunol Lett. 2005 Nov 15;101(2):202-9.

PMID:
16023736
41.

Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.

Atkins DJ, Gingert C, Justenhoven C, Schmahl GE, Bonato MS, Brauch H, Störkel S.

Virchows Arch. 2005 Sep;447(3):634-42. Epub 2005 Jul 1.

PMID:
15991006
42.

Decreased bone mineral density in patients with neurofibromatosis 1.

Lammert M, Kappler M, Mautner VF, Lammert K, Störkel S, Friedman JM, Atkins D.

Osteoporos Int. 2005 Sep;16(9):1161-6. Epub 2005 Jun 30.

PMID:
15988556
43.

[The German Guideline Clearinghouse on Breast Cancer: the need for frequent updating of breast cancer guidelines requires effective guideline updating procedures].

Weingart O, Sonntag D, Trapp H, Bartsch HH, Baumeister RG, Goerke K, Giersiepen K, Hindenburg HJ, Ming K, Schulz-Wendtland R, Störkel S, Kober T, Thole H, Kirchner H, Ollenschläger G; Guideline clearing house on breast cancer.

Z Arztl Fortbild Qualitatssich. 2004 Aug;98(5):403-11. German.

PMID:
15487388
44.

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.

Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S.

J Histochem Cytochem. 2004 Jul;52(7):893-901.

PMID:
15208356
45.

Molecular pathology of renal cell carcinoma.

Störkel S.

Urologe A. 2004 Sep;43 Suppl 3:S118-9. No abstract available.

PMID:
15164177
46.

[Choristoma in the vocal fold].

Kempf HG, Störkel S.

HNO. 2005 Apr;53(4):361-3. German.

PMID:
15127147
47.

[Prognostic parameters in renal cell carcinoma--a new approach. 1989].

Störkel S, Thoenes W, Jacobi GH, Lippold R.

Aktuelle Urol. 2004 Feb;35(1):18-21. German. No abstract available.

PMID:
15046020
48.

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.

Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B.

Int J Cancer. 2004 Mar 20;109(2):265-73.

49.

Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?

Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B.

J Urol. 2004 Feb;171(2 Pt 1):885-9.

PMID:
14713847
50.

Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors.

Hechelhammer L, Störkel S, Odermatt B, Heitz PU, Jochum W.

Virchows Arch. 2003 Jul;443(1):28-31. Epub 2003 Jun 3.

PMID:
12783324

Supplemental Content

Loading ...
Support Center